Inari Medical to Announce Second Quarter 2022 Financial Results
Inari Medical (NASDAQ: NARI) will announce its Q2 2022 financial results on August 3, 2022. A conference call is scheduled for 2:00 PM PT to discuss these results and recent highlights. The company specializes in medical devices for treating venous diseases, offering minimally invasive catheter-based solutions like the ClotTriever and FlowTriever systems, which are FDA-cleared and CE-marked for clot removal. Investors can join the conference call after registering.
- Scheduled Q2 2022 financial results announcement may indicate potential growth.
- Innovative product offerings include FDA-cleared ClotTriever and FlowTriever systems.
- None.
IRVINE, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its second quarter 2022 financial results on Wednesday, August 3, 2022. In conjunction with the release, Inari will host a conference call and webcast at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call.
The live webinar may be accessed by visiting the Events Section of the Inari investor relations website at ir.inarimedical.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on Inari’s website.
About Inari Medical, Inc.
Inari Medical, Inc. is a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases. Inari’s current product offering consists of two minimally invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and clot in transit in the right atrium.
Investor Contact:
ICR Westwicke
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com
FAQ
When will Inari Medical release its Q2 2022 financial results?
What time is the conference call for Inari Medical's Q2 2022 results?
How can I access Inari Medical's conference call?
What products does Inari Medical offer?
